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Abstract
Vitamin C is the major antioxidant molecule in the central nervous system (CNS), reaching 
concentrations of 10 mM in neurons and 400 μM in the cerebrospinal fluid (CSF). Uptake 
of vitamin C by brain cells is performed through the co‐transporter of ascorbic acid and 
sodium isoform 2, SVCT2, which is expressed in cells from the choroid plexus, neurons, 
oligodendrocytes, and ependymal cells. SVCT2 expression has also been described in 
cells at the neurogenic niche, specifically in proliferative type C cells. In this chapter, we 
will describe recently published studies of SVCT2 expression during brain development 
and define its polarization in cells from the radial glia (neuronal precursors within the 
CNS) and vitamin C‐mediated effects in regulating genes associated with the mainte‐
nance of CNS stem cell pluripotency. We will discuss the differential biological effect that 
vitamin C generates in neurons versus astrocytes and how the oxidized form of vitamin 
C, dehydroascorbic acid (DHA), produced by neurons in conditions of oxidative stress 
must leave this cell to be incorporated by astrocytes. In this context, we will discuss recent 
literature, which shows that DHA regulates glycolytic metabolism in neurons. In parallel, 
we will analyze vitamin C recycling by astrocytes, which reduce DHA into ascorbic acid 
(AA), increasing the antioxidant potential of the brain. Data discussed in this chapter will 
provide an updated view of SVCT2 distribution in the brain and will also describe how 
vitamin C recycling participates in normal or pathological brain function.
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1. Introduction
Vitamin C is a small, water‐soluble molecule that possesses two dissociable protons with 
pK values of 4.2 and 11.8. At physiological pH, the reduced form of vitamin C, ascorbic acid 
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(AA), predominates and is specifically incorporated by neurons through isoform 2 of the 
cotransporter of sodium and ascorbate (SVCT2) [1]. Once AA loses its protons, it is oxidized 
into dehydroascorbic acid (DHA), which diffuses among nervous cells through the facilita‐
tive glucose transporters, GLUT1 and GLUT3 [2–4]. Most mammals are able to synthesize 
vitamin C from glucose in the liver; however, primates, including humans, lack the enzyme 
that catalyzes the last step in vitamin C biosynthesis. Thus, they must obtain vitamin C from 
the diet [5, 6]. The most relevant function of vitamin C is as an antioxidant agent. Given that 
the brain has one of the highest metabolic rates of all organs and is under constant oxidative 
stress, vitamin C is, therefore, critical for the maintenance of brain function and protection of 
central nervous system (CNS) structures [5].
2. Distribution and function of SVCT2 in the adult brain
Many studies indicate that SVCT2 is a transporter that is preferentially expressed in neurons 
from different areas in the adult brain, such as the cortex, hippocampus, hypothalamus, and 
cerebellar precursors [1, 7–11]. SVCT2 mediates uptake of AA, an important molecule for 
antioxidant defense and general metabolic needs of neurons. Although SVCT2 was originally 
thought to be a neuronal transporter, there is increasing evidence demonstrating its expres‐
sion in glial cells in the CNS [4, 7, 8, 10, 12–14]. Indeed, SVCT2 has been reported in cortical 
microglia, where its function remains unknown [10]. In hypothalamic tanycytes, it may par‐
ticipate in maintaining the high parenchymal concentrations of vitamin C that characterize 
this region [8]. Furthermore, in choroid plexus cells, it facilitates entry of AA into the brain 
through the blood‐cerebrospinal fluid (CSF) barrier [4, 7, 10, 12]. In Schwann cells, SVCT2 
promotes axonal myelination in the peripheral nervous system [14]. Under physiological 
conditions, SVCT2 protein has not been detected in astrocytes from the gray matter, but its 
mRNA has been reported in marginal astrocytes in the subpial surface at the entorhinal cor‐
tex [13]. In contrast, SVCT2 mRNA is induced in the brains of animals with middle cerebral 
artery occlusion as an experimental model of ischemia/reperfusion in the brain, suggesting 
that expression of this transporter is induced under pathological conditions [15]. Moreover, 
our group has recently defined that SVCT2 protein is induced in reactive astrocytes in various 
in vivo pathological models that generate severe reactive astrogliosis. Specifically, such events 
involve neuroinflammation generated by intracerebroventricular injection of adenovirus‐GFP 
or the bacterial enzyme, neuraminidase, mechanical damage of the brain cortex evaluated 
at 5 and 10 days post‐injury, and astrogliosis observed in the brain cortex and hippocampus 
from “Kindled” rats, a widely used model of epilepsy at the mesial temporal lobe [16, 17]. In 
vitro studies support these findings by showing that SVCT2 is induced in astrocytes that have 
been cultured for long periods and express markers of astrocytic activation [3]. However, we 
did not observe a positive correlation between SVCT2 expression and the moderate and focal 
reactive astrogliosis surrounding amyloid plaques in postmortem brain samples from patients 
with Alzheimer’s disease. Altogether, data indicate that SVCT2 is induced in astrocytes during 
pathophysiological events that produce severe reactive astrogliosis, which may be important 
to enhance antioxidant defense in order to protect glial cells.
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3. Expression and polarization of SVCT2 during brain development
Studies published more than a decade ago have unequivocally demonstrated the expression 
and functionality of SVCT2 in cultured cortical neurons from mouse embryos [18]. Similarly, 
studies addressing the effect of physiological brain concentrations of AA have shown that this 
nutrient promotes differentiation of embryonic cortical precursors into neurons and astro‐
cytes [19]. Expression and polarization of SVCT2 have been studied during rat and human 
embryonic development in the cortex at 9 weeks of gestation [20, 21]. In lissencephaly, SVCT2 
is localized in radial glial cells in the ventricular zone, where it is polarized toward the ven‐
tricular cavity, and in subapical and intermediate apical progenitors in the subventricular 
zone [21]. In gyrencephalic brains, SVCT2 localization is also associated with progenitors of 
the inner and outer areas of the subventricular zone [21]. In vitro studies with J1ES cells, a cell 
model used to evaluate radial glial cell differentiation, indicate that both AA and SVCT2 are 
key regulators in maintaining the radial phenotype. They also may regulate the pluripotency 
of neural stem cells, as AA induces the expression of the pluripotency gene, Nanog, through 
activation of the JAK/STAT signaling pathway and inhibition of retinoic acid‐dependent neu‐
ronal differentiation [21, 22].
During postnatal brain development, levels of SVCT2 mRNA and protein follow an inverse 
relation with AA concentrations [23]. Thus, high concentrations of AA exist during late embry‐
onic and early postnatal development periods at both the cortex and cerebellum, diminishing 
later in adulthood; however, levels of SVCT2 mRNA and protein are low during embryonic 
development but increase with age [23]. By means of confocal and immune‐structural studies, 
our research group has identified SVCT2 in the Golgi apparatus of pyramidal neurons from 
the deep layers of the brain cortex (layers IV to VI) in early postnatal mice (days 1 and 5 after 
birth). These findings indicate that SVCT2 is induced during cell arborization and synaptic 
maturation of deep neurons in the brain cortex. We also identified the expression of a short 
isoform of SVCT2 (SVCT2sh), which is unable to transport AA and regulate the functional 
capacity of the active transporter [1]. This finding and its biological consequence in the post‐
natal brain will be discussed in the following section.
SVCT2 knock‐out mice (SLC23a2 null) have been critical to understanding the physiological 
importance of SVCT2 in the postnatal brain [24]. Although the intrauterine development of 
these animals looks normal, homozygote mice that lack SVCT2 present with brain cortex hem‐
orrhage and are unable to expand their lungs, resulting in death a few minutes following birth. 
Also, SVCT2‐null animals have undetectable levels of AA in their brain tissue, supporting the 
essential role of this transporter in AA entry into cells of the CNS. The defects characterized in 
SVCT2 knock‐out animals suggest that their death was due to CNS problems, possibly gener‐
ated by a deficit in individual neuronal function, formation of aberrant connections in the cortex 
and/or other brain areas, or lack of neuronal differentiation in the absence of AA [9]. Further 
studies have demonstrated that SVCT2 expression is pivotal for neuronal differentiation and 
maturation, since cultures of hippocampal neurons from knock‐out mice have reduced neu‐
rite growth, glutamate receptor aggregation, and spontaneous activity [9]. Lentiviral‐mediated 
overexpression of SVCT2 in cells of neuronal linage (N2a) allowed us to demonstrate a three‐ to 
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four‐fold increase in the percentage of cells with increased filopodia numbers and processes 
that were positive for the dendritic marker, microtubule‐associated protein 2 (MAP2) [25]. 
Furthermore, overexpression of SVCT2 combined with AA treatment promotes phosphoryla‐
tion of the mitogen‐activated protein kinase (MAPK), ERK1/2, a key signaling pathway interme‐
diate that participates in the differentiation and maturation of cortical neurons [25].
The hypothesis that SVCT2 and AA can potentiate neurogenesis during postnatal development 
has also been validated by Pastor et al. [26], who reported the postnatal expression of SVCT2 
in the neurogenic niche from rat and human brains after 1 month of extra‐uterine life [26]. 
This is a restricted area that borders the wall of lateral ventricles in which a stream of progeni‐
tor cells that migrate toward the olfactory bulb originate (called the rostral migratory stream 
[RMS]). SVCT2 is abundant in cells with high proliferative capacity in the neurogenic niche 
(also known as type C cells) and migratory progenitor cells present at the RMS. In contrast, 
among the different cell types of the neurogenic niche, SVCT2 is only present at low levels in 
astrocytes or type B cells and neuroblasts [26]. These findings suggest a role for AA in the main‐
tenance of proliferative cells, which, in turn, is supported by studies indicating that treatment 
with AA improves the genetic reprogramming of human fibroblasts into induced pluripotent 
stem cells (iPSC), enhancing the efficiency of the process and allowing the generated iPSC to 
present similar epigenetic patterns to those present in embryonic stem cells [27]. Moreover, 
AA supplementation of neurosphere cultures obtained from rat embryonic brain tissue and a 
teratocarcinoma cell line from P19 mice shows the functionality of SVCT2‐mediated uptake of 
AA as well as neuronal differentiation revealed by the increased expression of the marker, βIII 
tubulin [26].
In conclusion, SVCT2 is expressed at low levels during embryonic development, and its local‐
ization is restricted to the ventricular zone from cerebral ventricles, where the bodies of the 
radial glia are present. During this period, SVCT2 and AA are key players in regulating plu‐
ripotency and the proliferative capacity of neural stem cells. During postnatal development, 
AA and SVCT2 are important for postmigratory neurons that are beginning the process of 
arborization and synaptic maturation.
4. Regulation of SVCT2‐mediated vitamin C uptake in neurons by 
shSVCT2
As mentioned in the previous chapter, SVCT2 expression and function are important for the 
arborization and synaptic maturation of post‐mitotic neurons present in the postnatal brain 
cortex. However, during this period, SVCT2 function is tightly regulated by the co‐expres‐
sion of a shorter isoform of SVCT2, SVCT2sh, which is unable to transport AA. This isoform 
was initially identified in human fetal brain cDNA [28] and is generated by deletion of an 
internal sequence of 345 bp in the mRNA, resulting in the translation of a smaller protein 
completely lacking intracellular domains 5 and 6 and part of domain 4. SVCT2sh was initially 
thought to be a possible dominant negative of SVCT2 through protein‐protein interaction [28]. 
However, Forster resonance energy transfer (FRET) studies, a decade later using SVCT2‐CFP 
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and SVCT2sh‐YFP in the neural linage cell line, N2a [1], showed that the proteins interact at 
both the intracellular space and the cell membrane. The functional consequence of the inter‐
action reduces the affinity of SVCT2 for its substrate, AA, in neuronal cells, suggesting that 
SVCT2 activity and intracellular concentrations of AA are tightly modulated during postnatal 
development in order to generate a precise physiological intracellular dose of AA to trigger 
the neuronal differentiation and synaptic maturation in a particular period of development.
5. Vitamin C recycling
5.1. General aspects
In order to understand the concept of vitamin C recycling, it is necessary to remember that vita‐
min C is found in two forms: (1) a reduced form, AA, that enters the cells specifically through 
SVCT transporters and (2) an oxidized form, DHA, that enters the cells through the facilitative 
glucose transporters, GLUT1, GLUT2, GLUT3, GLUT4, and GLUT8 [29–31]. These two forms 
of vitamin C represent two different molecules with independent functions and characteris‐
tics, although they are interconvertible by means of oxidation‐reduction reactions [32]. Because 
every cell in the body expresses glucose transporters, all cells can uptake vitamin C in the form 
of DHA [2]. However, for intracellular accumulation of AA and antioxidant protection, the cell 
needs to reduce DHA into AA, a process that depends on glutathione and NADPH [33–35]. 
Therefore, the ability of a cell to accumulate AA via reduction of DHA is limited by its anti‐
oxidant enzymatic capacity. Interestingly, two different cell populations have been identified: 
cells with high and those with low antioxidant enzymatic capacity. Cells with low antioxi‐
dant enzymatic capacity preferentially use AA for protection against oxidative damage. Once 
AA accomplishes its antioxidant function, it is oxidized into DHA. Because these cells cannot 
reduce DHA back into AA, the presence of neighboring cells with high reducing power is 
crucial. Hence, DHA leaves the cell through glucose transporters and enters neighboring cells 
that possess an elevated concentration of antioxidant enzymes to reduce DHA into AA. Finally, 
AA can be accumulated or released into the extracellular space to maintain constant AA con‐
centrations. Therefore, ideal conditions exist in vivo to allow coupling between cells in order to 
efficiently recycle vitamin C.
5.2. Vitamin C recycling between astrocytes and neurons
The idea of vitamin C recycling in the brain originated from the observation that during nutri‐
tional deficiency of vitamin C, high AA concentrations in the brain are maintained for a longer 
period compared to all the other tissues [36, 37]. Thus, efficient mechanisms must exist to 
maintain AA concentrations in the brain. As mentioned before, in order for vitamin C recy‐
cling to occur, a cell with low reducing power that utilizes AA as an antioxidant is required in 
addition to a cell with high reducing power that is constantly incorporating DHA and releas‐
ing AA to the extracellular space. The ideal conditions for vitamin C recycling converge in the 
CNS, where we find two cell populations that couple in order to recycle vitamin C. On one 
hand, we find the neuron that is able to intracellularly accumulate up to 10 mM AA but rapidly 
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oxidizes it into DHA, which leaves the cell [4]. Furthermore, the neuron possesses a very lim‐
ited capacity to reduce DHA back into AA due to low concentration of antioxidant enzymes 
and its elevated metabolic rate [38]. Accordingly, isolation of neurons from the neighbor cells 
that recycle DHA compromises their metabolism, resulting in neuronal death [32, 39].
On the other hand, another cell type is found in the CNS, the astrocytes. For a long time, astro‐
cytes were only thought to be scaffold cells in the brain, without any physiological function. 
However, today we know that astrocytes perform critical physiological activities, such as (1) 
the uptake of extracellular glutamate for recycling into glutamine to avoid neuronal excito‐
toxicity; (2) the release of lactate to be used by neurons for energy production; (3) the release 
of interleukin‐6 (IL‐6) and tumor growth factor‐beta (TGF‐beta) neuroprotective cytokines; 
(4) the synthesis of apolipoprotein E for axonal growth; and (5) the release of trophic factors, 
such as nerve growth factor (NGF), brain‐derived neurotrophic factor (BDNF), and ciliary 
neurotrophic factor (CNTF), among others [40]. Moreover, astrocytes are required for vitamin 
C recycling in the CNS due to their ability to uptake DHA from the extracellular space and, in 
virtue of its elevated reducing power, to efficiently reduce it back into AA [41, 42]. After that, 
astrocytes release AA to the extracellular space to maintain stable AA concentrations [43]. 
Besides, astrocytes participate in the neuronal antioxidant defense by releasing AA during 
pathological conditions that involve changes in the osmotic pressure or ischemic/reperfusion 
damage [44]. Experiments using neuronal‐astrocyte co‐cultures have demonstrated that the 




 or DHA in 
vitro [39, 45], suggesting that astrocytes and vitamin C recycling are of vital importance for 
antioxidant defense in the brain.
6. Relevance of DHA recycling
6.1. Effects of DHA in neurons
As previously described, the neuron utilizes AA as the main antioxidant agent, but it is 
unable to maintain vitamin C in its reduced form. The effects triggered by the accumula‐
tion of DHA in neurons have begun to be elucidated recently. The first studies were focused 
in determining the effect of the extracellular oxidation of AA over the redox state of the 
neuron, showing that incubation of brain slices with exogenous AA produces an increase 
in thiobarbituric acid reactive substances (TBARS) [46–48], an indicator of oxidative dam‐
age. However, this effect was prevented by treatment with glutathione, indicating that AA 
oxidation might induce an increase in reactive oxygen species (ROS). It is widely accepted 
that AA oxidation generates ROS through the Fenton reaction, which occurs in the presence 




. AA creates the conditions for the Fenton 
reaction to occur, so AA might induce an increase in ROS and trigger cell death due to extra‐




 [49, 50]. Nevertheless, no increase in TBARS occurs when DHA 
uptake is prevented by inhibition of GLUT1 in brain slices, indicating that the pro‐oxidant 
effect requires DHA uptake by nervous cells and does not depend directly on AA oxidation 




 [47]. Additionally, as previously described, the pro‐oxidant effect 
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of AA disappears when it is co‐incubated with glutathione, even when glutathione reduces 
DHA into AA [33]. Thus, we can conclude that extracellular DHA accumulation due to an 
oxidative environment stimulates its uptake by neurons, which, in turn, induce oxidative 
stress because neurons possess low reducing power. Although these results constitute strong 
evidence suggesting that DHA might be triggering oxidative stress and neuronal death, the 
ultimate intracellular effect as well as the DHA target has not been identified. Further studies 
of our research group have shed light on the actual effect of DHA on neurons. Radioactive 
vitamin C uptake analyses have shown that neurons are able to incorporate both AA and 
DHA; however, their ability to reduce DHA is limited up to 40% after which they start to 
oxidize AA back into DHA. Moreover, neurons cannot keep AA in its reduced form for long 
periods, since it consumes 80% of intracellular AA after 1 h of uptake. However, in the pres‐
ence of DHA, neurons consume 90% of glutathione in 1 h. Therefore, our group has defined 
that the neuronal target of DHA is glucose metabolism since incubation with DHA induces 
a 75% arrest in glycolysis accompanied by increased activity of the pentose phosphate path‐
way, possibly to regenerate glutathione and avoid oxidative damage [32]. In conclusion, as 
shown in Figure 1, neurons need neighboring cells to recycle vitamin C in order to maintain 
stable concentrations of AA.
6.2. Relevance of astrocytes for DHA recycling
In order to confirm the hypothesis that the presence of vitamin C‐recycling cells is neces‐
sary, our research group performed studies of cell viability in neurons subjected to oxida‐




 and incubation with DHA. The aim of this experiment was 
Figure 1. Recycling of vitamin C in physiological and pathophysiological condition. Under physiological conditions, 
neurons uptake AA through the SVCT2 transporter. AA fulfills its antioxidant function intracellularly, oxidizing to 
DHA. Following DHA efflux from the neuron through GLUTs 1/3, astrocytes incorporate DHA that was released from 
the neuron, to reduce it intracellularly to AA at the expense of GSH and NADPH. Finally, the astrocyte releases AA into 
the extracellular medium to maintain a homeostatically stable concentration of AA. In pathophysiological conditions, 
vitamin C recycling is deficient; therefore, DHA accumulates in the extracellular space, recycling in an autocrine fashion 
toward the neuron. Accumulation of DHA in the neuron arrests glycolysis, consumes glutathione, and finally triggers 
cell death.
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to elucidate the dichotomy existing between the protective and toxic effects that DHA may 
produce. Given that the literature proposes antioxidant effects for DHA treatment in patho‐




, the major ROS accumulated in the 
extracellular space during pathological conditions of the brain (e.g., ischemia/reperfusion), 
and expected a depletion of the antioxidant enzymatic defense of the neuron [52]. In this 
experimental setting, we incubated neurons with DHA to assess for any antioxidant effect. 




 and DHA induced 50 and 70% cell death after 3 and 6 h, 




 alone [39]. The findings that 
neurons are inefficient in reducing DHA and that DHA accumulation induces cell death led 
us to the following question: how do neurons avoid DHA accumulation in physiological and/
or pathological conditions? The answer is the presence of another population of brain cells: 
the astrocytes. To analyze if astrocytes prevent the toxic effects of DHA, neuron‐astrocyte co‐
cultures using the sandwich technique were used to assess any protective effect of astrocytes 









and astrocytes were added to the culture just before DHA was added. Notably, neurons co‐
cultured with astrocytes showed 100% survival after 3 and 6 h of treatment, compared with 
neurons cultured alone [39], demonstrating that astrocytes are highly efficient in the recycling 
of DHA from the extracellular medium and that accumulation of DHA due to deficient astro‐
cyte recycling or severe oxidative conditions is toxic for neurons.
7. Conclusions
The relationship between vitamin C and brain pathologies remains a topic of discussion in 
the current literature, especially given that the oxidized form of vitamin C, DHA, has been 
largely ignored. DHA is actually a molecule that has great relevance for the treatment of vari‐
ous pathologies, including cancer, although conclusions observed when using DHA should be 
taken with caution. Indeed, DHA was originally proposed as a molecule that would be ben‐
eficial in pathological conditions, such as ischemia and reperfusion [51]. Unfortunately, the 
research group that proposed DHA as a treatment for ischemia and reperfusion subsequently 
determined that its administration in primate models did not replicate the results observed in 
rodents [53]. In these experiments, the researchers did not consider that the observations could 
be attributed to a failure in vitamin C recycling. Although vitamin C deficiency in the brain 
has been associated with increased oxidative stress, which could be stimulating ideal condi‐
tions to trigger certain pathologies, including Alzheimer’s disease [54], DHA has recently been 
proposed as a molecule that would trigger neuronal death [39]. As shown in Figure 1, we pro‐
pose that CNS pathologies could be associated with reduced astrocytic vitamin C recycling, 
resulting in the accumulation of DHA in neurons, which would trigger cell death.
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